Promotion at EGEN
This article was originally published in Scrip
EGEN, a US biopharmaceutical company specialising in nucleic acid therapeutics and delivery, has promoted Dr Jason Fewell from director of biology and pharmacology to vice-president of preclinical research and development.
You may also be interested in...
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.
The company’s third-quarter sales were up 4% year-over-year as transcatheter aortic valve replacement procedure volumes returned to pre-pandemic levels.